Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
| ▸ | SYK | P43405 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.47 |
| ▸ | MEF2D | Q14814 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | PLAU | P00749 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11518974 | 0.84 | SYK (0.57) | TP53CYP3A4HTTHSD17B10SYK | |
| SCHEMBL38660068 | 0.84 | MTNR1A (0.41) | TP53CYP3A4HTTHSD17B10SYK | |
| SCHEMBL27536474 | 0.84 | THRB (0.58) | KMT2ANR1H4CYP1A2CYP2C19TSHR | |
| SCHEMBL8306841 | 0.82 | APP (0.58) | TP53CYP3A4HTTHSD17B10SYK | |
| SCHEMBL38660132 | 0.82 | MTNR1B (0.57) | TP53HTTSMN1; SMN2KMT2AALDH1A1 | |
| SCHEMBL42399 | 0.82 | MTNR1B (0.57) | TP53HTTSMN1; SMN2KMT2AALDH1A1 | |
| SCHEMBL8349740 | 0.82 | SYK (0.50) | SYKALDH1A1LMNANR1H4CYP1A2 | |
| SCHEMBL8292685 | 0.82 | ALDH1A1 (0.48) | HTTHSD17B10SYKKMT2AALDH1A1 | |
| SCHEMBL9145377 | 0.82 | POLB (0.51) | TP53CYP3A4HTTHSD17B10SYK | |
| SCHEMBL10992519 | 0.82 | CYP3A4 (0.47) | TP53CYP3A4HTTHSD17B10SYK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130143824-A1 | COMPOSITIONS AND METHODS FOR ENHANCING APOPTOSIS | GENENTECH, INC. (US) | 2013-06-06 | — | — | US | claimed |
| US-20120058953-A1 | COMPOSITIONS AND METHODS FOR ENHANCING APOPTOSIS | GENENTECH, INC. (US) | 2012-03-08 | — | — | US | claimed |
| US-20110039324-A1 | COMPOSITIONS AND METHODS FOR ENHANCING APOPTOSIS | GENENTECH, INC. (US) | 2011-02-17 | — | — | US | claimed |
| US-20090148921-A1 | Compositions and methods for enhancing apoptosis | GENENTECH, INC. (US) | 2009-06-11 | — | — | US | claimed |
| EP-1590666-B1 | COMPOSITIONS AND METHODS FOR ENHANCING APOPTOSIS | GENENTECH INC (US) | 2008-07-09 | — | — | EP | claimed |
| EP-1590666-A4 | COMPOSITIONS AND METHODS FOR ENHANCING APOPTOSIS | GENENTECH INC (US) | 2006-07-26 | — | — | EP | claimed |
| EP-1590666-A1 | COMPOSITIONS AND METHODS FOR ENHANCING APOPTOSIS | Genentech, Inc. (US) | 2005-11-02 | — | — | EP | claimed |
| US-20040171554-A1 | Compositions and methods for enhancing apoptosis | GENENTECH, INC. | 2004-09-02 | — | — | US | claimed |
| WO-2004072641-A1 | COMPOSITIONS AND METHODS FOR ENHANCING APOPTOSIS | GENENTECH, INC. (US) | 2004-08-26 | — | — | WO | claimed |
| CN-103958487-B | Benzoic acid derivative as EIF4E inhibitor | 霍夫曼-拉罗奇有限公司 | 2016-07-13 | — | — | CN | disclosed |
| CN-103958487-A | Benzoic acid derivatives as eif4e inhibitors | HOFFMANN LA ROCHE | 2014-07-30 | — | — | CN | disclosed |
| CN-1993323-B | Indole, indazole or indoline derivatives | HOFFMANN LA ROCHE | 2011-04-20 | — | — | CN | disclosed |
| US-7928135-B2 | Benzene, pyridine, and pyridazine derivatives | SERENEX, INC. (US) | 2011-04-19 | — | — | US | disclosed |
| US-20110039838-A1 | PYRROLOTRIAZINE COMPOUNDS AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2011-02-17 | — | — | US | disclosed |
| US-20080096887-A1 | cell proliferation, such as cancer, inflammation, and angiogenesis; fungal infections; antimalaria; Heat hock protein 90 (HSP-90) inhibitor | SERENEX, INC. | 2008-04-24 | — | — | US | disclosed |
| US-7297695-B2 | Pyrrolotriazine compounds as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-11-20 | — | — | US | disclosed |
| CN-1993323-A | Indole, indazole or indoline derivatives | HOFFMANN LA ROCHE (CH) | 2007-07-04 | — | — | CN | disclosed |
| US-4172944-A | Water insoluble styryl dyestuffs having hetero-aryl methylene substituent | BAYER AKTIENGESELLSCHAFT (DE) | 1979-10-30 | — | — | US | disclosed |
| US-4046771-A | GREENISH-YELLOW SHADES ON SYNTHETIC FIBERS | BAYER AKTIENGESELLSCHAFT (DT) | 1977-09-06 | — | — | US | disclosed |
| US-4016191-A | WATER INSOLUBLE; LIGHTFASTNESS | BAYER AKTIENGESELLSCHAFT (DT) | 1977-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110039838-A1 | PYRROLOTRIAZINE COMPOUNDS AS KINASE INHIBITORS | ERBB2, ERBB4, ERBB3 | TP53 416/4885CYP3A4 1863/4885HTT 1673/4885 |
| US-20080096887-A1 | cell proliferation, such as cancer, inflammation, and angiogenesis; fungal infections; antimalaria; Heat hock protein 90 (HSP-90) inhibitor | HSP90AA1, HSP90AB1, HSPA4 | TP53 216/4885CYP3A4 1143/4885HTT 545/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.